BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:REGEND003 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of REGEND003\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07275788-479@assetmemo.bio
DTSTAMP:20261121T005347Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:REGEND003: Phase 1 readout est. (NCT07275788)
DESCRIPTION:REGEND003\, phase 1\, Type 2 Diabetes.\nStudy: A Study of REGEN
 D003 on Patients With Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney D
 isease (CKD)\nEstimated primary completion: December 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/regend003#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07275788
URL:https://assetmemo.bio/drug/regend003#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
